Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Azithromycin Ophthalmic Solution Articles

Merck & Co makes $430 million bid for Inspire, getting hands on eye drug Azasite

6 April 2011

Inspire Pharma abandons CF drug to focus on eye care business

22 February 2011

InSite's AzaSite cleared in Canada for pink eye

2 April 2009

Inspire/InSite's AzaSite debuts in the USA

20 August 2007

Inspire to sell $75M of stock

30 July 2007

InSite and Inspire in ocular antibiotic deal

26 February 2007

InSite prepares NDA on AzaSite

4 July 2005

InSite wins Azalide eye care EPO patent

20 June 2005

InSite enters AzaSite supply deal

23 May 2005

InSite Vision completes $16.5M placing

21 June 2004

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS